We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

MFIC Corporation Unveils Microfluidics Reaction Technology for Drug Formulation

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

MFIC Corporation has presented a discovery in their development program called Microfluidics Reaction Technology (MRT) during a poster presentation at the Nano Science and Technology Institute (NSTI) Nanotech 2007 Conference on Tuesday, May 22, 2007.

MRT provides the next-generation in nanosuspension processes to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs.

“The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader,” said Bob Bruno, President & COO.

“We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics,” added Bruno.

MRT advances the manufacturing of nanosuspensions bottom up by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in an efficient manner.

MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer® reaction chamber, which is based on impinging jet principals. The system provides control of the feed rate and mixing location.

“Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory,” said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study.

“Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods,” concluded Dr. Panagiotou.